Abstract 997P
Background
Microvascular invasion (MVI) is an independent poor factor for early recurrence (ER) and long-term outcomes in hepatocellular carcinoma (HCC) after hepatectomy. A practical, convenient, and accurate risk classifications is urgently needed to predict ER risk in HCC patients with MVI and to guide those patients to choose suitable adjuvant therapies to reduce postoperative recurrence risks and prolong long-term survival.
Methods
Data of 440 HCC patients with MVI after curative hepatectomy were retrospectively reviewed. They were randomly divided into a training set and a validation set. Kaplan-Meier curves and Cox regression analyses were used to identify independent prognostic factors of ER. Classification and regression tree (CART) analysis was used to develop ER risk classification in the training set and verified in the validation set.
Results
Multivariate analysis revealed that seven factors, namely, hepatitis B virus deoxyribonucleic acid load, tumor size, Edmondson-Steiner grade, MVI classification, satellite nodules, Ki67 positive index, and cytokeratin 19 expression were independent risk indexs for ER in HCC patients with MVI. The CART strategy showed a good concordance statistics of 0.77 in predicting ER risk, and had a better net benefit and a wider threshold probability range, as well as had a good agreement between the predicted value and actual observed value. The area under the time-dependent receiver operating characteristic curve of the CART strategy in predicting 1-, 3-, and 5-years recurrence-free survival (RFS) were 0.75, 0.78, and 0.84, respectively, and the corresponding overall survival (OS) were 0.74, 0.74, and 0.72, respectively, which were all significantly higher than other eight commonly classic HCC system stages (BCLC stage, Okuda stage, TNM stage, CNLC stage, French stage, CLIP score and JIS score). The ER, RFS and OS were greatly discrepancies between patients that had been stratified into three risk groups. Similar results were obtained in the validation set.
Conclusions
The CART strategy achieved optimal prediction for ER, RFS and OS for HCC patients with with MVI after curative hepatectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This research was supported by the National Natural Science Foundation of China (NO. 82060427, 82103297), Guangxi Key Research and Development Plan (NO. GUIKEAB19245002), Guangxi Scholarship Fund of Guangxi Education Department, Guangxi Natural Science Foundation (NO. 2020GXNSFAA259080).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
735P - Causes of death in a complete cohort of testicular cancer patients diagnosed in Norway 1980-2009, with detailed treatment information
Presenter: Øivind Kvammen
Session: Poster session 18
736P - Residual masses after salvage chemotherapy in men with metastatic seminoma: The Semi-ResMass multicenter retrospective study
Presenter: Giulia Baciarello
Session: Poster session 18
737P - Vascular fingerprint tool to identify testicular cancer patients at high-risk for early cardiovascular events after cisplatin-based chemotherapy
Presenter: Andrea Meuleman
Session: Poster session 18
738P - Penile squamous cell carcinoma with high and very high tumor mutational burden (TMB): A genomic landscape and "real-world" clinical outcome study
Presenter: Joseph Jacob
Session: Poster session 18
739P - Penile squamous cell carcinoma tissue associated macrophages captured by multiplex immunfluorence are associated with clinical outcomes
Presenter: Jad Chahoud
Session: Poster session 18
827P - Mutational spectra of the Korean patients with germline predisposition in hematologic malignancies: Five years of experience at a tertiary university hospital
Presenter: In-Suk Kim
Session: Poster session 18
828P - Clinical features and outcomes of neurologic paraneoplastic syndromes in Hodgkin lymphoma
Presenter: Benjamin McCormick
Session: Poster session 18
829P - Age and sex related genomic profiles of follicular lymphoma
Presenter: Robin Imperial
Session: Poster session 18
830P - Isolation of cell-free DNA of patients with mucosa-associated lymphoid tissue (MALT) lymphoma
Presenter: Julia Berger
Session: Poster session 18
831P - Decitabine sensitized TP53-mutated diffuse large B cell lymphoma to R-CHOP treatment via activation of endogenous retrovirus
Presenter: Li Wang
Session: Poster session 18